ArticleThe Journal of nutrition2025
Nonfat Milk Supplementation Mitigates Hepatic Lipid Accumulation and Improves Hepatic Lipid Metabolism in an Early Metabolic Dysfunction-Associated Steatotic Liver Disease C57BL/6N Mouse Model.
Article in The Journal of nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Early-Life Dietary Protein Source Reshapes Gut Microbiota but Fails to Curtail Diet-Induced Metabolic Syndrome in Young Rats.Obesity (Silver Spring, Md.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDairy products may mitigate metabolic dysfunction-associated steatotic liver disease (MASLD) progression, but the role of dairy fat is unclear.
objectivesThis animal trial compared MASLD-related outcomes after feeding nonfat milk (NFM) or whole-fat milk (WFM) in a high-fat diet (HFD)-induced MASLD mouse model.
methodsMale C57BL/6N mice were fed a HFD (45% kcal fat; n = 40) for 9 wk. During the last 8 wk, 2 randomly selected groups additionally consumed 0.425 mL NFM (0 g% fat; n = 8) or WFM (3.25 g% fat; n = 12), from a small dish, 5 d/wk. A low-fat diet group (10% kcal fat; n = 20) served as a reference. The metabolic phenotype and liver lipid metabolism pathways were studied and compared by 1-way analysis of variance; P ≤ 0.05 was considered significant.
resultsNFM reduced body weight (BW) gain (46 ± 2.5 compared with 61 ± 3.5 %BW, P < 0.01) and hepatic triglyceride content (46.0 ± 10.4 compared with 71.7 ± 14.4 mg/g, P <0.05) compared with HFD. Immunoblotting revealed that NFM feeding increased hepatic mitochondrial complex abundance (P < 0.05) compared with WFM. Compared with NFM, WFM had higher triglyceride content (69.2 ± 16.5 compared with 46.0 ± 10.4 mg/g, P < 0.05) but reduced liver area covered by lipid droplets in comparison with HFD (6.49 ± 2.75 compared with 13.61 ± 2.75% standard area, P = 0.051). De novo lipogenesis enzymes, fatty acid synthase (1.33 ± 0.56 compared with 0.76 ± 0.56 AU, P < 0.05) and phosphorylated acetyl-CoA carboxylase (1.65 ± 0.49 compared with 0.02 ± 0.49 AU, P < 0.05) were increased compared with NFM. Carnitine palmitoyl transferase 1α (1.48 ± 0.19 compared with 1.00 ± 0.19 AU, P < 0.05) was increased in WFM compared with HFD animals, and Opa1 mRNA expression was increased in WFM (1.26 ± 0.21 compared with 0.66 ± 0.21 AU, P < 0.05) compared with the NFM group.
conclusionsCompared with WFM, NFM mice had greater benefits in mitigating MASLD progression through increased capacity for oxidative phosphorylation and fatty acid export, leading to reduced hepatic fat accumulation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.